3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
5
Acrocephalosyndactylia
5
Neoplasm Metastasis
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Radiotherapy
54
Temozolomide
50
Filgrastim
25
Cyclophosphamide
25
Etoposide
24
Cisplatin
22
Carboplatin
22
Vincristine
19
Chemotherapy, Adjuvant
18
Peripheral Blood Stem Cell Transplantation
15
Thiotepa
13
Carmustine
12
Thalidomide
10
Methotrexate
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Bevacizumab
9
Granulocyte Colony-Stimulating Factor
7
sargramostim
6
Topotecan
6
Lomustine
6
X-Rays
5
Tamoxifen
5
Specimen Handling
5
Phantoms, Imaging
5
O(6)-benzylguanine
5
Ifosfamide
5
Erlotinib Hydrochloride
5
Drug Therapy
5
Celecoxib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Central Nervous System Neoplasms
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts